How the Euripid collaboration contributes to price transparency of pharmaceuticals
Habl, Claudia; Fischer, Stefan; (2021
Spending on pharmaceuticals is growing continuously with a forecast of reaching over one trillion Euro in the next five years. Also, the average price of newly launched medicines is steeply raising. To manage high launch prices, public payers in Europe more and more rely on private law contractual arrangements with pharmaceutical companies, requiring significant price discounts and other types of managed-entry agreements (MEAs).
In spring 2021 we analysed the EURIPID database for occurrence and frequency of MEA in the 28 countries
